Clinical Trial

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

Study acronym: TRuE-AD5
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated June 16, 2026 (before its estimated July 13, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of the study is to assess the efficacy and safety of ruxolitinib cream in children and adolescents (6 to \<18 Years Old) with moderate atopic dermatitis.
Protocol Amendment History 24 amendments
This ClinicalTrials.gov record has been amended 24 times since 2025-02-12; most recent amendment 2026-06-15.
Status change: Recruiting → Active, Not Recruiting 2026-06-15
Status change: Not Yet Recruiting → Recruiting 2025-05-27
Trial Details
NCT Number NCT06832618
Lead Sponsor Incyte Corporation
Conditions Atopic Dermatitis
Enrollment 159 participants
Start Date 2025-06-17
Primary Completion 2026-07-13 (estimated)
Study Completion 2028-05-18 (estimated)
Updated on ClinicalTrials.gov 2026-06-16